Syngene International Limited has informed the Exchange about Investor Presentation
Ref: Syn/CS/SE/IP/2026-27/Apr/10
April 30, 2026
To, The Manager, BSE Limited Corporate Relationship Department Dalal Street, Mumbai – 400 001 Scrip Code: 539268
Dear Sir/Madam,
Syngene International Limited Syngene International Limited Biocon SEZ, Biocon Park, Plot No. 2 & 3, Biocon SEZ, Biocon Park, Plot No. 2 & 3, Bommasandra Industrial Area, IV Phase, Bommasandra Industrial Area, IV Phase, Jigani Link Road, Bengaluru 560099, Jigani Link Road, Bengaluru 560099, Karnataka, India. Karnataka, India. T +91 80 6891 9191 T +91 80 6891 8000 CIN: L85110KA1993PLC014937 F +91 80 6891 8808 www.syngeneintl.com CIN: L85110KA1993PLC014937 www.syngeneintl.com
To, The Manager, National Stock Exchange of India Limited Corporate Communication Department Bandra (EAST), Mumbai – 400 051 Scrip Symbol: SYNGENE
Sub: Investor Presentation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
With reference to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the Investor Presentation for the quarter and year ended March 31, 2026. The Company will use this presentation for any meeting scheduled with analysts or institutional investors.
The above-mentioned Investor Presentation will also be available on the website of the Company www.syngeneintl.com.
This is for your information and records.
Thanking You,
Yours faithfully,
For SYNGENE INTERNATIONAL LIMITED
______________ Chethan Yogesh Company Secretary and Compliance Officer
Enclosed: Investor Presentation.
Phase, Phase,
B o B m o m m a m s a a s n a d n r d a r I a n I d n u d s u t s r t i r a i l a A l r A e r a e , a I , V I V B o B m o m m a m s a a s n a d n r d a r I a n I
Investor Presentation
April 2026
Safe harbour
Certain statements in this release concerning our future growth prospects are forward-looking statements, which are subject to a number of risks, uncertainties and assumptions that could cause actual results to differ materially from those contemplated in such forward-looking statements.
Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, business outlook of our clientele and their research and development efforts, our ability to successfully implement our strategy, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global biotechnology and pharmaceuticals industries, increasing competition, changes in political conditions in India and changes in the foreign exchange control regulations in India.
Neither the Company, nor its directors and any of the affiliates have any obligation to update or otherwise revise any statements reflecting circumstances arising after this date or to reflect the occurrence of underlying events, even if the underlying assumptions do not come to fruition.
Putting Science to Work
2
Contents
1
2
3
4
5
Q4 FY26 Highlights
Syngene – Putting Science to Work
Syngene strengths
Financials
Shareholding and Share Information
Putting Science to Work
3
1
Q4 FY26 Highlights
Q4 and FY26 performance
Operating Highlights
Q4 FY26 Financial Highlights
▪ ADC Platform Expansion: Commenced operations at the ADC discovery laboratory during the
quarter, complementing the recently added GMP bioconjugation suite and establishing end-to- end ADC capabilities from discovery to manufacturing
▪ Quality & Regulatory: Completed 14 audits during the quarter (FY total: 85) and obtained Good Clinical Practice – National Accreditation Board for Testing and Calibration Laboratories (GCP- NABL) accreditation, reinforcing adherence to globally recognized standards for clinical research and data quality
Revenue from Operations Rs 1,037 Cr ( 2% Y-o-Y) ~USD 112 Mn
Operating EBITDA margin 29% (34% in Q4 FY25)
PAT before exceptional items : Rs. 153 Cr (-16%YoY)
▪ Sustainability & ESG: Included in the S&P Global Sustainability Yearbook 2026, ranking in the top 10 life sciences companies and top 9% globally; also recognised as an ‘Industry Mover’ for the highest year-on-year improvement in its Corporate Sustainability Assessment score
FY26 Financial Highlights
▪ Key management changes:
- Kiran Mazumdar-Shaw transitioned from Non-Executive Chairperson to Executive
Chairperson, effective 1 April 2026, for a five-year term
Revenue from Operations Rs 3,739 Cr ( 3% Y-o-Y) ~USD 419 Mn
Operating EBITDA margin 25% (29% in FY25)
- Siddharth Mittal appointed Managing Director & Chief Executive Officer, effective 1 July
2026, succeeding Peter Bains. He joins from Biocon Limited, where he served as Managing Director and CEO
- Maninder Kapoor Puri appointed Chief Human Resources Officer and Executive Committee member, effective 1 May 2026, and Abhijit Zutshi appointed Chief Commercial Officer and Executive Committee member, effective 1 May 2026; both previously held leadership roles at Biocon
PAT before exceptional items : Rs. 380 Cr ( -20% YoY)
Putting Science to Work
5
2
Syngene – Putting Science to Work
Partner in innovation: #Putting Science to Work
Who we are and what we do We aim to be a world class partner delivering innovative scientific solutions for clients
We offer integrated solutions across research, development and manufacturing
Sector expertise include pharmaceuticals, biotech, nutrition, animal health, consumer goods and specialty chemicals
Our team includes more than ~5,700+ scientists out of total 8,300+ headcount, operating across 4 global state-of-the-art campuses located in India’s leading life science hubs: Bangalore, Mangalore, Hyderabad and USA (Baltimore)
Established track record in discovery research and development/ manufacturing for small and large molecules
Putting Science to Work
7
Our journey so far
Globalization and strategic collaboration • Expanded into formulations development • Contract with Endo Pharmaceuticals to develop novel anti cancer
biological therapeutic molecules • Extension of collaboration with BMS; • Merger of Clinigene • Crossed annual turnover of Rs. 5 Billion
Foundation • Operations started • Expansion of R&D Lab • Granted 100% EOU status
by the Government of India
1993 – 2000
2010 – 2014
2001 – 2009
Expansion • Expanded service offerings to
include chemical development, safety assessment, biologics development
• Collaboration with BMS to set
up BBRC, Syngene’s first dedicated R&D Center
2019 – 2026
Continued investments and growth •
Laboratory capacity expansion in Bangalore and Hyderabad
• Expansion in Mangalore for commercial API
manufacturing
• Capacity and capability addition in Biologics
manufacturing
• Entered in long-term partnership with Zoetis
for Biologics commercial-scale manufacturing
• Acquired multi-modal biologics
manufacturing facility from Stelis Biopharma Ltd
• Acquired 17 acres land in Hyderabad to support long term growth in research business
• Acquired, state of the art first biologics site in Baltimore, USA taking Syngene’s total single-use bioreactor capacity to 50,000L invested in new capabilities and emerging modalities, such as peptides and ADCs, ensuring alignment with growing global demand
•
Putting Science to Work
8
2015 – 2018
IPO and further collaborations • IPO and listing • Collaboration with Amgen to set up a dedicated R&D center
Key facts and figures
~400 active clients
16 out of top 20 pharma companies are clients
400+ patents held with clients
World class infrastructure International presence with global campuses across Bangalore, Hyderabad and Mangalore in India and Baltimore in USA qualified to meet international standards
Rs. 3,739 Cr (~US$419 Mn) FY26 Revenue from operations
Rs. 380 Cr** FY26 PAT
8,373 headcount including 5,778 talented scientists
92% energy from renewable sources*
All figures are as on March 31, 2026 / FY2026, unless otherwise specified *As on March 31, 2025 **before exceptional items
Putting Science to Work
9
Syngene – one of the largest integrated CRDMO players in India
One-stop platform for integrated drug discovery, development and manufacturing across modalities
Expanding capacity
Building capabilities for future
Building partnerships
(in Million sq. ft.)
3+
(#)
8,373
(#)
0.9
3,526
~400
250+
March’16 FY16
March’26 FY25
March’16 FY16
March’26 FY26
March’16 FY16
March’26 FY24
More than tripled the infrastructure that is qualified to meet international standards
Over 2.5x employees from FY16 comprising talented scientists
Over 50% increase in active clients 16 out of top 20 pharma companies are clients
• Expanded laboratory capacity in Bangalore and Hyderabad
• ~5,700+ scientists comprising PhDs, MS
• Expanded partnerships with big pharma and emerging
• Expanded to Mangalore for commercial API manufacturing
• Acquired land in Hyderabad for long term growth in research
business
• Acquired multi-modal biologics facility from Stelis Biopharma Ltd
• Acquired first biologics site in the USA from Emergent
Manufacturing Operations Baltimore, LLC
• US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC
accredited and GLP certified facilities
• Skills and experience to become trusted thought
partner in cutting-edge research
• Scientific prowess across modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
• Proven success in delivering integrated CMC
programs and clinical candidates
biopharma
• Expanded into commercial manufacturing in Biologics
with Zoetis
• Enhanced BD presence across key value clusters
including US and Europe
• 25-year strategic partnership with BMS – established BBRC, India’s first and largest dedicated R&D center
Putting Science to Work
10
3-pronged growth strategy across diversified platform
Discovery Services
Dedicated R&D Centers
T&CR
Large Molecule CDMO
Small Molecule CDMO
Research Services (CRO)
Flexible Platform with capability across multiple modalities including small molecule, large molecule, peptides, oligonucleotides, antibody drug conjugates, PROTACs
SynVent - proprietary platform for Integrated Drug Discovery
SARchitect- proprietary platform for data visualization and analysis. Enables collaboration between scientific experts across geographies
Ring-fenced infrastructure for exclusive operations for an individual client
Comprehensive research services through trials conducted on both healthy volunteers and patients
Dedicated multi-disciplinary team of scientists
Access to entire Syngene ecosystem for specialist research and development operations
• Human Pharmacology Unit (Phase I/BE
studies)
• Clinical Trial Services – full solution provider for conducting global trials
• Translational services- a continuum from preclinical to clinical trials
• Regulated bioanalysis for large and
small molecules
• Central Laboratory
Process development
Manufacturing of large molecules for clinical/commercial supplies
Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate
cGMP-compliant facilities
State-of-the art Biologics manufacturing facilities with international presence
Drug substance and drug product development
Associated services to demonstrate the safety, tolerability and efficacy of the selected drug candidate
cGMP-compliant manufacturing of clinical supplies, and registration batches for small molecules
Manufacturing of small molecules for commercial supplies
State-of-the art API manufacturing facility
Putting Science to Work
11
Our Strategy
Research Services
Provide an integrated end-to-end therapeutic discovery services Encompassing drug discovery, pre- clinical and clinical development capabilities across technologies, platforms, disciplines, disease areas and therapeutic modalities.
Development and Manufacturing Services – Large Molecules
Implement a comprehensive strategy for biologics development and manufacturing, establishing a seamless, one-stop-shop capability that covers everything from drug discovery to commercial production.
Operational Excellence
People
Drive operational excellence through improved reliability, speed and efficiency to enhance customer delivery and satisfaction.
Build a future ready, high-performance organization by nurturing leadership at all levels, fostering holistic employee well-being, and driving a culture of continuous growth and innovation
Development and Manufacturing Services – Small Molecules
Utilize existing Chemistry, Manufacturing, and Controls (CMC) capabilities and commercial manufacturing, while also developing innovative technologies, to establish a fully integrated, cutting-edge small molecule development and manufacturing service provider
Environmental, Social and Governance (ESG)
Syngene is committed to responsible and sustainable growth, ensuring that its ESG standards meet the evolving expectations of clients, investors, and stakeholders. Our ESG strategy is a key enabler of long-term value creation, embedding environmental stewardship, social responsibility, and robust governance across all aspects of our operations
Putting Science to Work
12
3
Syngene strengths
Syngene strengths
A global scale CRDMO player •
Integrated Drug Discovery, Development and Manufacturing service provider
• Small and large molecules, ADCs, oligonucleotides • Listed on Indian Stock Exchanges (NSE and BSE)
Solutions through innovation • IP fully assigned to clients • Track record of data management and
security
• Over 400+ patent filings by clients recognizing Syngene scientists
Quality matters • Fully digitized quality organization • Strong compliance track record with global regulators • US FDA, EMA, UK VMD, Health Canada, PMDA approved, AAALAC
accredited and GLP certified facilities
• 85 client and regulator audits in the last financial year
Science in our DNA • Global presence : India life science hubs: Bangalore,
Mangalore and Hyderabad & Baltimore, USA
• ~5700+ qualified scientists including ~500 PhDs (8,300+ total
headcount) Resilient supply chain management
• • 3 Mn+ sq. ft world-class R&D and manufacturing
infrastructure
Blue chip client list • ~400 active clients • Partnering with large / mid-size / emerging
biopharma and other industries
• Clients concentrated in US, Europe & Japan • Track record of working with diverse industry
sectors
Making a difference • Partnerships have delivered numerous clinical candidates • Delivery history for integrated CMC programs up to clinical trials and beyond
Putting Science to Work
14
Experienced workforce: building capabilities and careers
Inspiring technical excellence and providing opportunities to grow
8,373 total headcount
5,778 scientists delivering high quality solutions – create a competitive edge
7% PHDs
Empowering our workforce
• Thrive360 operating philosophy embedding wellbeing into how work is designed and
delivered - supporting physical, mental & emotional, social, financial and career wellbeing
• Future-focused performance and career conversations that build capability, clarify growth
pathways and strengthen engagement and retention
• Enterprise-wide leadership and manager capability development to build strong people
leadership and succession depth
Continuous learning & development
• Scientific skills development to standardise and advance scientific and technical upskilling
across the organization
• Supporting talent stability and execution continuity during a demanding operating environment
Shaping a culture of belonging
•
Inclusive culture broadening access to scientific and leadership talent
• Diverse teams strengthening innovation and problem-solving
• 27% women representation overall and 19% women in senior management
All figures are as on March 31, 2026
Putting Science to Work
15
Extended our state-of-the-art infrastructure & new capabilities with global presence to meet our strategic partners needs
HQ campus at Bangalore, India 90 Acres where most of Syngene’s capabilities are housed today
Fully functional R&D Centre at Genome Valley, Hyderabad, India
USA based Biologics facility Bayview, Baltimore, USA
Biologics Discovery development & and manufacturing plants in Bangalore, India
API manufacturing Commercial manufacturing to support product launch located at Mangalore, India
Putting Science to Work
16
We currently operate a range of successful collaboration models
Dedicated R&D Labs
Full time equivalent (FTE)
Fee For service (FFS)
Risk / Reward Model
• Customers receive ring-fenced infrastructure customized to their research needs
• Dedicated scientific and support teams work exclusively on the customer’s projects
• Long-term strategic partnerships, typically extending for five years or more, foster deep collaboration and sustained innovation
• A dedicated team of scientific personnel from predefined disciplines works exclusively on the customer’s projects
• Deliverables and team
composition evolve as the project progresses to align with changing requirements
• Agreements are typically
renewed annually, ensuring continuity and flexibility
• Services are provided within a defined scope
• Flexible, on-demand
personnel and research infrastructure are allocated to meet project objectives
• Engagements can be short- term or long-term, based on project requirements
• A milestone-driven approach covering a portfolio of research projects
• Customers benefit
from reduced upfront costs, with payments tied to predefined success milestones
5
Outcome – based model with Service Level Agreement
• A contract structured
around the achievement of predefined outcomes
• Linked to specific
productivity goals to ensure performance-driven results
… and are open to any single or combination of above
Putting Science to Work
17
Our experience spans multiple industry segments and partners us with global leaders across the world…
Large & Mid-Sized BioPharma
Emerging BioPharma (EBP)
Animal Health
AgroChem
CPG
Chemicals/ Polymers
Note : This is a representative selection of the customers Syngene works with. We work with ~ 400 customers across industry segments .All product names, logos, brands, trademarks and registered trademarks are the property of their respective owners
Putting Science to Work
18
Operational robustness driving strategy execution
Continuous improvement embedded through a structured Lean Six Sigma framework Certification pathway from White Belt to Master Black Belt 90+ Green Belts and 60+ Black Belts driving operational excellence 10+ Master Black Belts anchoring enterprise-level transformation
Quality management system: digitized and audit-ready 85 customer and regulator audits in the last FY 6 successful USFDA audits in the last 5 years
Client-focused commercial organization Leaders based in the US, Europe, UK and Asia close to client locations
Focused execution through strong Project Management Structured program management for executing client projects enabled by SynPro platform and SynPro Academy ensuring delivery of client projects
Digital as a differentiator AI capability in all research teams Integrating automation, IT solutions, and data analytics, we optimize workflows, enhance resource allocation and utilization, and ensure regulatory compliance
Strategic Sourcing that makes a difference Effective global collaboration with 2,800+ suppliers across 30 countries
Building a resilient supply chain amid geopolitical uncertainty through robust logistics network, dual sourcing strategy, and domestic supplier development for critical raw materials.
Putting Science to Work
19
Syngene digital initiatives aimed at driving innovation and operational
At Syngene, IT strategy is closely aligned with organizational priorities, emphasizing investments in automation and digitization to improve scientific and enterprise functions.
Initiatives to automate and integrate core business processes, enhancing Syngene’s digital presence and customer engagement.
Comprehensive 1-3-5-year roadmap to future-proof operations and build next- generation digital capabilities, with an emphasis on AI adoption
Accelerating Digital Transformation at Syngene
Driving Enterprise- Wide Transformation
Strengthening Scientific Operations
Automate workflows, eliminate errors, and improve execution quality
Certification as per ISO 13485:2016, ISO/IEC 27001 and ISO 9001:2015 requirements
“Fail fast” approach to AI and GenAI, launching small-scale pilots to quickly test feasibility, assess early outcome
Enabling AI- Powered Productivity
Fortifying Infrastructure and Information Security
Advanced IT and cybersecurity landscape with a One-Click Disaster Recovery system, CDC & ISWG
Putting Science to Work
20
Committed to safety and sustainability
Safety is our first priority •
Accredited with ISO 45001:2018 for Occupational Health and Safety (OH&S) measures
•
•
•
•
Risk assessments are an integral part of our operation
Kavach, our flagship safety program, has delivered improvement in safety metrics and drives focus on industrial safety for all employees
Lost time injury frequency rate (LTIFR ): 0.00
36,737 hours of EHSS training
Proud to be recognized by TIME Magazine and Statista as: • World’s Most Sustainable Companies 2025 • World’s Best Companies in Sustainable Growth 2026
Committed to environmental protection •
Committed to Science-based targets for greenhouse gases
•
•
•
•
•
•
•
95% of total hazardous and non-hazardous waste recycled
92% of energy procured from renewable energy sources
1,296 MT equivalent CO2 savings from energy conservation
73,313 tCO2e of GHG emissions avoided
64% YoY freshwater savings achieved
1,04,413 KL fresh water saved from recycling, reusing and rainwater harvesting
11,433 KL rainwater harvested
Refer to the CSR link on our website to know about our corporate social responsibility pursuits on healthcare, education, environment, rural development Refer to the Annual Report on our website to know more All figures are as on March 31, 2025, unless otherwise specified
Putting Science to Work
21
Accreditations
• USFDA, EMA, UK VMD, PMDA and Health Canada Certified GMP facilities.
• GLP, NABL (ISO IEC 17025) certification for Safety Assessment and Large Molecule Bioanalytical Laboratory
• GLP certification for Viral Testing Facility, AAALAC Accreditation and CCSEA registration for Safety Assessment
• USFDA, MHRA. AGES inspected & ANVISA approved Translational and Clinical research facility
•
•
ISO 15189:2012, NABL & College of American Pathologists (CAP) accredited Clinical and Molecular diagnostics facility
ISO 9001:2015, 14001:2015, 45001:2018, ISO 13485:2016, ISO 50001:2018 and ISO/IEC 27001:2022 accreditations.
Putting Science to Work
22
We have consistently received industry recognition for our scientific capability and business excellence
•
CMO Leadership Awards 2022 Presented by Life Science Leader and Outsourced Pharma
•
CMO Leadership Award Champion 2022 - Presented by Life Science Leader and Outsourced Pharma
• Golden Peacock Award for Excellence in Corporate Governance for 2021 by the Institute of
Directors at the 'Golden Peacock Awards Ceremony’
•
•
The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for ‘Best Unique or Innovative Leadership Program’ and ‘Best Advance in Compliance Training’
The 2022 Brandon Hall Group HCM Excellence Bronze Award In Leadership Development for
• Asia Pacific Biologics CMO Excellence Awards 2022 - For Quality •
Biopharma Honours Award 2022 - For Viral Testing Facility by Informa Markets
• Most Preferred Workplace 2022 - Award by MarksmenDaily.com
•
EcoVadis Sustainability Rating, 2024 : Syngene secured silver rating in the EcoVadis sustainability index for commitment to ESG practices and ranked among the top 15% of companies assessed worldwide.
• Asia Pacific Biologics CMO Excellence Awards 2024 : Adjudged Best Biologics CMO in South Asia by IMAPAC • Winner under the Reliability and Compatibility categories for exceeding customer expectations at CDMO
Leadership Awards 2024
• Declared champion by the Institute of Supply Chain Management (ISCM) at the Pharma Supply Chain
Management 5.0 summit.
• Award for Excellence in Environment Health and Safety (EHS) practices at CII-SR EHS Excellence Awards 2023 • Awarded India’s Best Managed Company by Deloitte • Golden Peacock Award 2023: For risk management practices under the Pharmaceutical sector category. •
Best Overall Sustainable Performance (Pharmaceutical) 2023 at the 2nd Edition India Sustainability Conclave & Awards 2023
2021
2022
2023
2024
2025-2026
• Dream Companies to Work Award at the 29th Edition of the World HRD
• Golden Peacock National Quality Award
Congress Awards.
• Asian Leadership Award for Excellence in Branding and Marketing in the
Contract Research Development and Manufacturing category
•
•
•
•
•
CRISIL awards Syngene Top score among Indian Pharma - for Environment Safety Governance (ESG)
Syngene ranked #69 in Fortune India magazine's list of 'Top 100 Indian wealth creators 2021’
India Pharma Awards 2021 for Operational Excellence– Manufacturing organized by Informa Markets, India
Best Governed Company in the Listed Segment: Medium Category at the 21st National Awards for Excellence in Corporate Governance by The Institute of Company Secretaries of India (ICSI)
Best Corporate Foundation Award at the World CSR Congress
2023 For meeting the overall requirements of the Golden Peacock Excellence Model
•
Biopharma Excellence Awards 2023 For Best Contract Development and Manufacturing Organization (CDMO)
•
•
•
•
•
CDMO Leadership Award 2025: Adjudged winner in the Biologics category by Outsourced Pharma and Life Science Connect.
Biopharma Excellence Awards 2025 (India Edition): Adjudged Best Bioprocessing Supplier – Analytical Services by IMAPAC.
Pharma Supply Chain Champion 2025: Ranked #1 among mid-sized pharma and API firms by the Institute of Supply Chain Management (ISCM).
TIME Magazine & Statista – World’s Most Sustainable Companies 2026: Ranked amongst the global top three and #1 in India in the Pharma & Biotech category; second recognition in six months.
S&P Global Sustainability Yearbook 2026: Ranked among the top 10 life sciences companies and the top 9% globally; recognised as an ‘Industry Mover’ for or achieving the highest year-on-year improvement in its Corporate Sustainability Assessment score.
• NAMC Gold Award: Biologics Manufacturing Excellence at the National Awards for Manufacturing
Competitiveness (NAMC).
• Achieved My Green Lab ‘Green Certification’ (>94% score) for laboratories •
EcoVadis 2025 score improved to 74/100, placing Syngene in the 91st percentile globally.
Note : This is a representative selection of awards received by Syngene and is not an exhaustive list
Putting Science to Work
23
Syngene has established an enterprise-wide risk oversight with clear accountability from management to the Board
Syngene’s enterprise-wide risk management framework provides a holistic approach to identification, monitoring, reporting and mitigating risks that could impact performance
Operating Unit / Enabling Function Heads Operational execution and risk ownership
• Own the identification and management of risks
•
•
Review risk registers and track mitigation actions
Escalate emerging risks and threshold breaches to the Executive Committee
• Align risk actions with operational priorities and performance goals
Executive Committee Strategic alignment and execution
Risk Management Committee Governance and oversight
Board of directors Strategic oversight
• Align risk management with strategic objectives, business planning and resource allocation
•
•
Identify and review key risks and their mitigation effectiveness
Promote cross functional risk collaboration
• Oversee risk management policy and
• Define and approve risk appetite
framework
statements
• Define and monitor risk appetite in co-
•
ordination with the Board
Set strategic direction for risk management
• Monitor risk exposure against defined
• Assess the performance of the Risk
limits
•
•
Review risk identification, assessment and rating processes
Evaluate the effectiveness of internal controls
Management Committee and overall ERM processes
Refer Annual report for complete risk profile and risk mitigation strategy
Putting Science to Work
24
4
Financials
Q4 FY26 financial highlights
All figures in Rs. Mn unless otherwise specified
Particulars
Q4 FY26 Q4 FY25 YoY change Q3 FY26 QoQ change
Revenue from operations
10,365
10,180
2%
Other income
222
189
17.5%
Reported revenue
10,587
10,369
Material costs
Staff costs
Other direct costs
Other expenses
2,331
3,316
260
2,350
2,794
221
1,216
1,333
Foreign exchange (gain)/loss, net
209
46
EBITDA
EBITDA Margin
Depreciation and Finance Cost
PBT
Tax
3,256
3,625
30.8%
35.0%
1,115
2,020
488
1,061
2,405
572
PAT before exceptional items
1,532 (3)
1,833
PAT Margin
14.5%
17.7%
2%
-1%
19%
17%
-9%
354%
-10%
5%
-16%
-15%
-16%
PAT after exceptional items
1,479
1,833
-19%
9,171
154
9,325
2,299
2,992
258
1,297
233
2,246
24.1%
1,256
990
261
729
7.8%
150
13%
44%
14%
1%
11%
1%
-6%
-10%
45%
-11%
104%
87%
110%
886%
Balance Sheet Highlights
As on 31st March 2026
All figures in Rs. Mn unless otherwise specified
Shareholders’ funds
Net Fixed assets
Other net assets (1)
Net cash/(debt) (2)
Total Use of Funds
48,391
40,456
-10,068
18,003
48,391
(1) Other Net Assets calculated as all assets other than cash and cash equivalents less all liabilities other than debt and shareholders equity (2) Net cash / (Net debt) calculated as the Cash & cash equivalents (Cash and bank balances + Current investments+ Fixed deposits) less Total debt (Short-term borrowings + Long-term borrowings) at the end of the year (3)
Excludes (i) a gratuity re measurement credit of Rs. 20 Cr. (net of tax) arising from revised labour codes, and (ii) expenses of Rs 25 Cr. (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy.
Putting Science to Work
26
FY26 financial highlights
All figures in Rs. Mn unless otherwise specified
Particulars
FY26
FY25
YoY change
Revenue from operations
Other income
Reported revenue
Material costs
Staff costs
Other direct costs
Other expenses
Foreign exchange (gain)/loss, net
EBITDA
EBITDA Margin
Depreciation and Finance Cost
PBT
Tax
37,387
36,424
707
718
38,094
37,142
9,186
9,425
12,297
10,792
1,029
5,082
609
9,891
26.0%
4,529
4,875
1,076
970
4,800
19
11,136
30.0%
4,326
6,279
1,530
PAT before exceptional items
PAT Margin
PAT after exceptional items
3,799(1)
4,749(2)
10.0%
3,167
12.8%
4,962
3%
-1%
3%
-3%
14%
6%
6%
3104%
-11%
5%
-22%
-30%
-20%
-36%
(1)
(2)
Excludes (i) impact of Rs. 38 Cr. (net of tax) pertaining to the net increase in gratuity liabilities on account of newly implemented labour codes, and (ii) expenses of Rs 25 Cr. (net of tax) recognised under Exceptional Items related to termination benefits extended to employees in accordance with the approved policy. Excludes an exceptional item of Rs 21 Cr. (net of tax) relating to the final settlement from an insurance claim.
Putting Science to Work
27
5
Shareholding and Share Information
Syngene and Biocon Group
Syngene is an operationally independent publicly listed subsidiary of Biocon Limited, established in 1993 as India’s first Contract Research Organization. The Company has 30+ years of experience in novel molecule discovery, development and manufacturing services
Biocon Limited, founded in 1978, is an innovation-led global biopharmaceuticals company and has majority holding in key operating entities including Syngene
Integrated services: • • • Manufacturing
Research Services Development and for
small/large molecules
• • •
•
Product Based Biosimilars Formulations and Compounds Alternative Therapeutic Drugs
Putting Science to Work
29
Shareholding and Share Information
Syngene’s shareholders*
1%
47%
Promoter & Promoter Group
53%
Public
ESOP Trust
Syngene’s Share Information*
NSE Ticker
BSE Ticker
Market Cap (Rs. Mn)
% free-float^
Free-float market cap (Rs. Mn)
Share Outstanding (Mn)
SYNGENE
539268
1,57,106
47%
74,337
403
• As on 31st March 2026 •
^ Free float includes shares held by public and in ESOP Trust
Putting Science to Work
30
For more details
Visit our website www.syngeneintl.com
https://www.linkedin.com/company/syngene-international-limited
https://www.youtube.com/channel/UCIC4WSA1k5YAC531gMLkbIQ
IR Contact: Nandini Agarwal investor@syngeneintl.com nandini.agarwal@syngeneintl.com
Media Contact: Vijay Jeevanandham E: Vijay.jeevanandham@syngeneintl.com
Putting Science to Work
31